Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:EVFM NASDAQ:NMTR NASDAQ:PBLA NASDAQ:TFFP On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeEVFMEvofem Biosciences$0.01-4.3%$0.01$0.01▼$0.02$1.06M-0.92427,425 shs348,628 shsNMTR9 Meters Biopharma$0.00$0.07▼$6.56$1.04M1.36315,915 shsN/APBLAPanbela Therapeutics$0.16-13.9%$0.24$0.10▼$0.47$777K1.3418,160 shs2,970 shsTFFPTFF Pharmaceuticals$0.07$0.06$0.06▼$3.23N/A0.981.04 million shsN/A10 Stocks Set to Soar in Summer 2025Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceEVFMEvofem Biosciences0.00%-4.30%-8.25%-1.11%-18.35%NMTR9 Meters Biopharma0.00%0.00%0.00%0.00%+6,463.64%PBLAPanbela Therapeutics0.00%-23.85%-31.03%-42.86%-54.29%TFFPTFF Pharmaceuticals0.00%0.00%0.00%0.00%-96.64%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationEVFMEvofem Biosciences1.1618 of 5 stars0.05.00.04.80.60.00.0NMTR9 Meters BiopharmaN/AN/AN/AN/AN/AN/AN/AN/APBLAPanbela Therapeutics0.3477 of 5 stars0.05.00.00.00.60.00.0TFFPTFF PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceEVFMEvofem Biosciences 0.00N/AN/AN/ANMTR9 Meters Biopharma 0.00N/AN/AN/APBLAPanbela Therapeutics 2.00HoldN/AN/ATFFPTFF Pharmaceuticals 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownCompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookEVFMEvofem Biosciences$11.39M0.09N/AN/A($2.64) per share0.00NMTR9 Meters BiopharmaN/AN/AN/AN/A$0.19 per shareN/APBLAPanbela TherapeuticsN/AN/AN/AN/A($18.37) per shareN/ATFFPTFF Pharmaceuticals$730K0.40N/AN/A$4.04 per share0.02Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateEVFMEvofem Biosciences$52.98M-$0.05N/A∞N/A-46.42%-91.97%-61.93%N/ANMTR9 Meters Biopharma-$43.77M-$3.46N/AN/AN/AN/A-584.97%-159.45%N/APBLAPanbela Therapeutics-$25.26M-$71.13N/A∞N/AN/AN/A-302.61%7/21/2025 (Estimated)TFFPTFF Pharmaceuticals-$21.24M-$6.440.00∞N/AN/AN/AN/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthEVFMEvofem BiosciencesN/AN/AN/AN/AN/ANMTR9 Meters BiopharmaN/AN/AN/AN/AN/APBLAPanbela TherapeuticsN/AN/AN/AN/AN/ATFFPTFF PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioEVFMEvofem BiosciencesN/A0.110.09NMTR9 Meters BiopharmaN/A0.590.59PBLAPanbela TherapeuticsN/A0.260.26TFFPTFF PharmaceuticalsN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipEVFMEvofem Biosciences0.22%NMTR9 Meters Biopharma22.34%PBLAPanbela Therapeutics4.37%TFFPTFF Pharmaceuticals15.25%Insider OwnershipCompanyInsider OwnershipEVFMEvofem Biosciences0.21%NMTR9 Meters Biopharma2.40%PBLAPanbela Therapeutics0.01%TFFPTFF Pharmaceuticals4.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableEVFMEvofem Biosciences120118.66 million113.12 millionNot OptionableNMTR9 Meters Biopharma2014.34 million13.99 millionNo DataPBLAPanbela Therapeutics64.86 million4.86 millionNot OptionableTFFPTFF Pharmaceuticals194.44 million4.24 millionOptionableTFFP, PBLA, EVFM, and NMTR HeadlinesRecent News About These CompaniesTFF Pharmaceuticals approves dissolution planMarch 8, 2025 | uk.investing.comTFF Pharmaceuticals Announces Delisting from Nasdaq and Potential SEC DeregistrationFebruary 6, 2025 | prnewswire.comTFF Pharmaceuticals Inc (TFFP) Stock: A Deeper Look at Its True PotentialDecember 12, 2024 | bovnews.comBThe TFFP Stock Mystery: Why Did TFFP Plunge Today?December 6, 2024 | bovnews.comBTFF Pharmaceuticals Inc (TFFP) Stock: More Robust Than the Numbers Suggest?November 23, 2024 | bovnews.comBStock Shock: The Unpredictable Rise and Fall of TFFP—What’s Driving the Drama?November 20, 2024 | bovnews.comBTFFP Unveiled: The Shocking Truth Behind TFF Pharmaceuticals Inc’s Latest Stock MovementsNovember 19, 2024 | bovnews.comBU.S. stocks lower at close of trade; Dow Jones Industrial Average down 0.70%November 15, 2024 | msn.comTFF Pharmaceuticals (TFFP) Takes a Dark Turn: What’s Next for Investors?November 15, 2024 | bovnews.comBTFF Pharmaceuticals Shares Fall 66%; Company to Wind DownNovember 14, 2024 | marketwatch.comTFF Pharmaceuticals terminates employees, to wind down operationsNovember 14, 2024 | markets.businessinsider.comTFF Pharmaceuticals to Dissolve and Liquidate AssetsNovember 14, 2024 | markets.businessinsider.comTFF Pharmaceuticals, Inc. Announces Termination of Employees and Wind Down of OperationsNovember 14, 2024 | quiverquant.comQTFF Pharmaceuticals Announces It Will Wind Down OperationsNovember 14, 2024 | globenewswire.comTFF Pharmaceuticals (NASDAQ:TFFP) Stock Quotes, Forecast and News SummaryOctober 9, 2024 | benzinga.comTFF Pharmaceuticals (TFFP) Upgraded to Strong Buy: Here's WhyOctober 8, 2024 | zacks.comTFF Pharmaceuticals, Inc.: TFF Pharmaceuticals' Technology Generates Superior Inhalational Dry Powder Formulations for Pulmonary Drug DeliverySeptember 26, 2024 | finanznachrichten.deTFF Pharmaceuticals’ Technology Generates Superior Inhalational Dry Powder Formulations for Pulmonary Drug DeliverySeptember 26, 2024 | markets.businessinsider.comPost-COVID Trends in Biopharma Contract ManufacturingSeptember 25, 2024 | contractpharma.comCThe Yadot Group to Acquire Experiential Agency Socials DallasSeptember 16, 2024 | dallasinnovates.comDNew MarketBeat Followers Over TimeTFFP, PBLA, EVFM, and NMTR Company DescriptionsEvofem Biosciences NASDAQ:EVFM$0.0089 0.00 (-4.30%) As of 07/18/2025 03:28 PM EasternEvofem Biosciences, Inc., a biopharmaceutical company, develops and commercializes various products to address unmet needs in women's sexual and reproductive health. Its commercial product is Phexxi, a vaginal gel for the prevention of pregnancy. The company is also involved in the development of EVO100 for the prevention of chlamydia and gonorrhea in Women, and EVO200 for the prevention of recurrent bacterial vaginosis. Evofem Biosciences, Inc. is headquartered in San Diego, California.9 Meters Biopharma NASDAQ:NMTR9 Meters Biopharma, Inc., a clinical-stage biopharmaceutical company, focuses on treatments for people with rare digestive diseases, gastrointestinal conditions with unmet needs, and debilitating disorders in North America. Its lead product candidate is Vurolenatide, a long-acting injectable glucagon-like-peptide-1 that is in Phase 3 clinical trial to treat short bowel syndrome. The company is developing NM-136, a humanized monoclonal antibody for the treatment of obesity and obesity-related disorders; NM-102, a small molecule peptide to prevent antigens from trafficking into systemic circulation; and NM-003, a proprietary long-acting glucagon-like peptide-2 receptor agonist for prevention of acute graft versus host disease. Its partnered product is Larazotide, an 8-amino acid peptide, which is in Phase 2 clinical trial for treatment of multi-system inflammatory syndrome. The company has licensing agreements with Amunix, MHS Care Innovation LLC, Alba Therapeutics Corporation, and EBRIS. 9 Meters Biopharma, Inc. is headquartered in Raleigh, North Carolina. On July 17, 2023, 9 Meters Biopharma, Inc. filed a voluntary petition for liquidation under Chapter 7 in the U.S. Bankruptcy Court for the Eastern District of North Carolina.Panbela Therapeutics NASDAQ:PBLA$0.16 -0.03 (-13.93%) As of 07/18/2025 03:46 PM EasternPanbela Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of disruptive therapeutics for the treatment of patients with urgent unmet medical needs. The company's lead product candidates are Ivospemin (SBP-101), a proprietary polyamine analogue, which has completed Phase Ia/Ib clinical trial for the treatment of patients with metastatic pancreatic ductal adenocarcinoma; Flynpovi, a combination of eflornithine (CPP-1X) and sulindac which is in Phase III clinical trials; and Eflornithine, an enzyme-activated irreversible inhibitor of the enzyme ornithine decarboxylase, currently under Phase I/II trial. It has a research agreement with the Johns Hopkins University School of Medicine for the development of ivospemin. The company was formerly known as Sun BioPharma, Inc. and changed its name to Panbela Therapeutics, Inc. in December 2020. Panbela Therapeutics, Inc. was incorporated in 2011 and is based in Waconia, Minnesota.TFF Pharmaceuticals NASDAQ:TFFPTFF Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on developing and commercializing drug products based on its patented Thin Film Freezing (TFF) technology platform in the United States and Australia. It intends to focus on the development of inhaled dry powder drugs for the treatment of pulmonary diseases and conditions. The company's drug candidates are TFF Voriconazole Inhalation Powder, which is in Phase II clinical trials for the treatment and prophylaxis of invasive pulmonary aspergillosis; and TFF Tacrolimus Inhalation Powder, which is in Phase II clinical trials used to prevent lung transplant rejection. It also develops other dry powder products, such as Augmenta human derived monoclonal antibodies for the treatment of COVID-19 disease; and other vaccines. It has a license agreement with the University of Texas at Austin for the development of inhaled dry powder drugs. TFF Pharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Fort Worth, Texas. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 07/14 - 07/18 Netflix Q2 2025 Earnings: What Investors Need to Know High-Flying GE Aerospace Drops After Blowout Q2 — What Now? A New $70 Billion AI Investment Could Push Taiwan Semiconductor Why Prologis May Be the Smartest Backdoor Bet on AI Real Estate Snap-On: Snap Up This Strong Signal While It’s Still Cheap Why Abbott Laboratories Is a Q2 2025 Buy: Growth & Yield Why Pure Storage Is a Core Investment for the AI Era Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
